Indivior (NASDAQ:INDV) Shares Gap Down - What's Next?

Indivior PLC (NASDAQ:INDV - Get Free Report) gapped down prior to trading on Tuesday . The stock had previously closed at $9.52, but opened at $9.23. Indivior shares last traded at $9.45, with a volume of 114,520 shares trading hands.

Analyst Ratings Changes

INDV has been the subject of several recent research reports. Piper Sandler dropped their price target on shares of Indivior from $16.00 to $13.00 and set an "overweight" rating for the company in a research report on Thursday, March 6th. RODMAN&RENSHAW raised Indivior to a "strong-buy" rating in a report on Tuesday, January 28th. Finally, Rodman & Renshaw assumed coverage on Indivior in a research note on Tuesday, January 28th. They issued a "buy" rating and a $16.00 price target on the stock.

Indivior Price Performance

The company's 50 day simple moving average is $10.86 and its two-hundred day simple moving average is $10.56. The stock has a market capitalization of $1.33 billion, a P/E ratio of -27.53 and a beta of 0.82.

Indivior (NASDAQ:INDV - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The company reported $0.32 earnings per share for the quarter, meeting analysts' consensus estimates of $0.32. The firm had revenue of $298.00 million during the quarter, compared to analysts' expectations of $262.35 million. Indivior had a negative return on equity of 241.73% and a negative net margin of 3.96%. On average, research analysts anticipate that Indivior PLC will post 1.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in INDV. Valence8 US LP bought a new position in shares of Indivior in the third quarter worth about $564,000. Clark Estates Inc. NY bought a new position in Indivior in the 3rd quarter worth approximately $2,477,000. Stonepine Capital Management LLC acquired a new position in Indivior during the 3rd quarter worth $2,632,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Indivior by 4.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 41,327 shares of the company's stock valued at $408,000 after buying an additional 1,888 shares during the last quarter. Finally, Rockefeller Capital Management L.P. increased its stake in shares of Indivior by 66.7% in the 3rd quarter. Rockefeller Capital Management L.P. now owns 50,000 shares of the company's stock valued at $488,000 after buying an additional 20,000 shares during the period. Institutional investors and hedge funds own 60.33% of the company's stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Remove Ads